Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Lorenz Deutschenbaur, Johannes Beck, Anna Kiyhankhadiv, Markus Mühlhauser, Stefan Borgwardt, Marc Walter, Gregor Hasler, Daniel Sollberger, Undine E Lang
Major depression is a common, recurrent mental illness that affects millions of people worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has been observed by ketamine, which acts via the glutamatergic system. Hence, a steady accumulation of evidence supporting a role for the excitatory amino acid neurotransmitter (EAA) glutamate in the treatment of depression has been observed in the last years. Emerging evidence indicates that N-methyl-D-aspartate (NMDA), group 1 metabotropic glutamate receptor antagonists and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) agonists have antidepressant properties...
January 4, 2016: Progress in Neuro-psychopharmacology & Biological Psychiatry
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
